The wealth effect is an economic concept that describes how people’s spending behavior changes when their perceived wealth ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...

PRINCETON, NJ, USA I April 14, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the ...

Squibb “announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos for the treatment of adult patients with symptomatic New ...

The randomized, double-blind, placebo-controlled ODYSSEY-HCM trial included 580 adult patients with symptomatic nonobstructive HCM.

Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment ...

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Q1 2025 Earnings Conference Call April 17, 2025 2:30 AM ETCompany ParticipantsBen Page - Chief Executive OfficerDan Lévy - ...